October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

REGISTER NOW How do you decipher information from complex imaging technologies? Hyperplexing technologies have drastically increased the number of biomarkers that can be analyzed in tissue sections, but finding meaningful differences...

3DHISTECH UPGRADES PANNORAMIC® MIDI II, ITS BEST-SELLING SLIDE SCANNER FOR DIGITAL PATHOLOGY PANNORAMIC® MIDI II, 3DHISTECH’s best-selling member of the PANNORAMIC® scanner range is an award-winning all-round digital slide scanner...

Support for the American Cancer Society’s national Hope Lodge program enables a home away from home for patients and their caregivers. Philadelphia – December 5, 2019 – Proscia, a leading provider of AI-enabled digital pathology...

The Ibex Second Read™ System for breast is now deployed at Maccabi's pathology institute, making it the first lab in the world to implement AI-powered cancer diagnostics for breast biopsies in its routine clinical practice TEL AVIV,...

Aiforia announced today the release of its new product, the CE-IVD marked Aiforia® Clinical, as well as the award of €2.2 million in funding from the EU’s Horizon 2020 program. The EU grant was awarded to support Aiforia’s ongoing...

OR

platinum partners

gold partners

Silver Partners

Media Partners